Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Translational Medicine|November 1, 2005
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor RapamycinKerrington R Molhoek, David L Brautigan, Craig L Slingluff
Cancer Journal (Sudbury, Mass.)|August 10, 2010
Interface of signal transduction inhibition and immunotherapy in melanomaAmber L Shada, Kerrington R Molhoek, Craig L Slingluff
Cancer Immunology, Immunotherapy : CII|October 9, 2008
Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2Kerrington R Molhoek, Chantel C McSkimming, Walter C Olson, et al.
Cancer Research|June 4, 2008
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2Kerrington R Molhoek, Heinrich Griesemann, Jianfen Shu, et al.
Melanoma Research|June 10, 2011
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1RKerrington R Molhoek, Amber L Shada, Mark Smolkin, et al.
Melanoma Research|September 22, 2010
Evaluation of molecular markers of mesenchymal phenotype in melanomaLeann M Mikesh, Manish Kumar, Gulsun Erdag, et al.
International Journal of Cancer|May 6, 2011
VEGFR-2 expression in human melanoma: revised assessmentKerrington R Molhoek, Gulsun Erdag, J K Rasamny, et al.
Journal of Translational Medicine|September 20, 2013
MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and BevacizumabAubrey G Wagenseller, Amber Shada, Kevin M D'Auria, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptidesRebecca C Harris, Kimberly A Chianese-Bullock, Gina R Petroni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)Craig L Slingluff, Gina R Petroni, Kerrington R Molhoek, et al.
Pageof 1